The restatement is a classification-only change with no impact on total net income, cash, or balance sheet, so it does not alter the company's fundamental financial position. Monitor the upcoming 10-Q for Q3 2026 for any further restatement disclosures or additional material weaknesses, and watch for the FDA PDUFA decision on Oxnimbi on February 28, 2027, which is the primary near-term catalyst.
Price Chart
Executive Summary
Apnimed filed Amendment No. 1 to its Q2 2026 Form 10-Q to restate its unaudited condensed consolidated financial statements for the three and six months ended June 30, 2026. The restatement reclassifies the $85.4 million gain on the sale of its SASS equity method investment from continuing operations (other income) to discontinued operations, per ASC 205-20. The restatement has no impact on total net income, total net income per share, total assets, total liabilities, total stockholders' equity, or net cash flows, and is attributed to a previously disclosed material weakness in internal control over financial reporting.
Key Facts
- Restates Q2 2026 (three and six months ended June 30, 2026) financial statements to reclassify the $85.4 million gain on the SASS Disposition from continuing operations to discontinued operations.
- Restatement has no impact on total net income, total net income per share, total assets, total liabilities, total stockholders' equity (deficit), or net cash flows from operating, investing and financing activities.
- As restated, net income from continuing operations for the three months ended June 30, 2026 is $40.7 million (previously $126.1 million); net income from discontinued operations is $85.2 million (previously $0).
- As restated, net income from continuing operations for the six months ended June 30, 2026 is $111.1 million (previously $196.5 million); net income from discontinued operations is $82.5 million (previously $0).
- Total net income for the three and six months ended June 30, 2026 is unchanged at $125.9 million and $193.7 million, respectively.
- Restatement attributed to a previously disclosed material weakness in internal control over financial reporting related to classification, valuation and disclosure of non-routine or complex transactions.
- Company filed an 8-K on November 13, 2026 disclosing the prior Q2 2026 financial statements should no longer be relied upon.
- Cash and cash equivalents as of June 30, 2026 were $172.8 million; accumulated deficit was $203.7 million.
- IPO completed in August 2026 raised approximately $200.4 million net proceeds at $16.00 per share.
- FDA PDUFA goal date for Oxnimbi (AD109) is February 28, 2027.
Financial Impact
Reclassification of $85.4 million gain on sale of SASS equity method investment from continuing operations to discontinued operations for both the three and six months ended June 30, 2026. No impact on total net income, total net income per share, total assets, total liabilities, total stockholders' equity, or net cash flows.
Risk Factors
- Restatement signals a material weakness in internal control over financial reporting that remains unremediated, which could lead to future misstatements or delays in financial reporting.
- The company's business is highly dependent on FDA approval of its sole clinical candidate, Oxnimbi, with a PDUFA goal date of February 28, 2027; failure to obtain approval would materially harm the business.
- Company has significant debt obligations including a $50.0 million Tranche A Term Loan and $35.0 million convertible notes, with covenants and collateral requirements that could restrict operations.
- The company expects to continue generating operating losses and negative cash flows for the foreseeable future and will require substantial additional funding.
Market Snapshot
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-Q/A Filing (Primary) | 0001193125-26-460871 |
| Document: apmd-ex31_2.htm | 0001193125-26-460871 |
| Document: apmd-ex31_1.htm | 0001193125-26-460871 |
| Document: apmd-ex32_1.htm | 0001193125-26-460871 |
| Document: apmd-ex32_2.htm | 0001193125-26-460871 |
| Document: 0001193125-26-460871-index-headers.html | 0001193125-26-460871 |
| Document: 0001193125-26-460871-index.html | 0001193125-26-460871 |
| Document: 0001193125-26-460871.txt | 0001193125-26-460871 |
Track record
11 reports on APMD
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +18.84% at T+20 after the Jul 31, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 5/10 Entry price pending
- Nov 13, 20263d ago 10-Q/A Neutral 4/10 Viewing Entry $17.41 Now $16.28 −6.49% settles Dec 15
- Nov 13, 20263d ago 8-K Bearish 6/10 Entry $17.41 Now $16.28 +6.49% settles Dec 15
- Nov 4, 202612d ago SC 13G Neutral 4/10 Entry $15.30 Now $16.28 +6.41% settles Dec 3
- Aug 5, 202614w ago Insider Cluster Bullish 7/10 Entry $27.88 to $27.81 Now $16.28 −41.61% ▼ −0.25% −0.85% vs SPY
- Aug 3, 202615w ago Insider Buy Bullish 7/10 Entry $25.71 to $26.85 Now $16.28 −36.68% ▲ +4.43% +5.67% vs SPY
- Jul 31, 202615w ago 424B4 Mixed 6/10 Entry $25.00 to $26.25 Now $16.28 −34.88% ▲ +5.00% +3.76% vs SPY
- Jul 31, 202615w ago EFFECT Bullish 7/10 Entry $25.00 to $29.71 Now $16.28 −34.88% ▲ +18.84% +15.85% vs SPY
- Jul 30, 202615w ago 3 Neutral 3/10 Entry $25.00 to $29.71 Now $16.28 −34.88% ▲ +18.84% +15.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers